Home | Contact Us
Roskamp Institute Patients, Families and Friends Healthcare Professionals Clinical Operations
Roskamp Institute
About Us How to Help News Careers Better science. Real discovery.

Articles and Publications

(1998 - present)

  1. Poon HF, Abdullah L, Reed J, Doore SM, Laird C, Mathura V, Mullan M, Crawford F. Improving image analysis in 2DGE-based redox proteomics by labeling protein carbonyl with fluoroscent hydroxylamine. Biol Proced Online. 2007 Dec 19;9:65-72. PMID: 18385803 [PubMed - in process]. PMCID: PMC2274965.
  2. Volmar CH, Ait-Ghezala G, Frieling J, Paris D, Mullan MJ. The granulocyte macrophage colony stimulating factor (GM-CSF) regulates amyloid beta (Abeta) production. Cytokine. 2008 Apr 21. [Epub ahead of print]. PMID: 18434187 [PubMed - as supplied by publisher]
  3. Mathura V, Paris D, Ait-ghezala G, Gupta P, Volmar C, Mullan M. A vector method for comparison of RNA and protein expression levels of cytokines upon CD40L treatment of microglia. IJIB. 2008 Aug;
  4. Mathura V, Rangareddy M, Gupta P, Mullan M. CliniProteus: A flexible clinical trials information management system. Bioinformation. 2007 Dec 28; 2(4): 163-165. PMCID: PMC2255069.
  5. Abdullah L, Paris D, Luis C, Quadros A, Parrish J, Valdes L, Keegan AP, Mathura V, Crawford F, Mullan M. The influence of diagnosis, intra- and inter-person variability on serum and plasma Abeta levels. Neurosci Lett. 2007 Nov 27;428(2-3):53-8. Epub 2007 Oct 2. PMID: 17964720 [PubMed - in process]
  6. Crawford FC, Wood M, Ferguson S, Mathura VS, Faza B, Wilson S, Fan T, O'Steen B, Ait-Ghezala G, Hayes R, Mullan MJ. Genomic analysis of response to traumatic brain injury in a mouse model of Alzheimer's disease (APPsw). Brain Res. 2007 Sep 25; [Epub ahead of print] PMID: 17961517 [PubMed - as supplied by publisher]
  7. Ait-Ghezala G, Volmar CH, Frieling J, Paris D, Tweed M, Bakshi P, Mullan M. CD40 promotion of amyloid beta production occurs via the NF-kappaB pathway. Eur J Neurosci. 2007 Mar;25(6):1685-95.
  8. Paris D, Patel N, Quadros A, Linan M, Bakshi P, Ait-Ghezala G, Mullan M. Inhibition of Abeta production by NF-kappaB inhibitors. Neurosci Lett. 2007 Mar 19;415(1):11-6. Epub 2006 Dec 27.
  9. Crowell TA, Luis CA, Cox DE, Mullan M. Neuropsychological comparison of Alzheimer's disease and dementia with lewy bodies. Dement Geriatr Cogn Disord. 2007;23(2):120-5. Epub 2006 Dec 5.
  10. Poon HF, Abdullah L, Mullan MA, Mullan MJ, Crawford FC. Cocaine-induced oxidative stress precedes cell death in human neuronal progenitor cells. Neurochem Int. 2007 Jan;50(1):69-73. Epub 2006 Sep 7.
  11. Paris D, Patel N, Quadros A, Linan M, Bakshi P, Ait-Ghezala G, Mullan MJ. Inhibition of Aβ production by NF-κB inhibitors. Neurosci. Lett. (2006), doi:10.1016/j.neulet.2006.12.029
  12. Crawford FC, Wood ML, Wilson SE, Mathura VS, Geall F, Kolippakkam DN, Mullan MJ. Cocaine induced inflammatory responses in human neuronal progenitor cells.   J Neurochemistry 2006 97:662-674
  13. Laporte V, Ait-Ghezala G, Volmar CH, Mullan M. CD40 deficiency mitigates Alzheimer's disease pathology in transgenic mouse models.   J Neuroinflammation 2006 3:3
  14. Crowell TA, Paramadevan J, Abdullah L, Mullan M. Beneficial effect of cholinesterase inhibitor medications on recognition memory performance in mild to moderate Alzheimer's disease: preliminary findings.  J Geriatr Psychiatry Neurol. 2006 Mar;19(1):13-5.
  15. Abdullah L, Ait-Ghezala G, Crawford F, Crowell TA, Barker WW, Duara R, Mullan M. The cyclooxygenase 2 -765 C promoter allele is a protective factor for Alzheimer's disease.  Neurosci Lett. 2006 395:240-243
  16. Borenstein AR, Mortimer JA, Wu Y, Jureidini-Webb FM, Fallin MD, Small BJ, Mullan M, Crawford FC. Apolipoprotein E and cognition in community-based samples of African Americans and Caucasians.  Ethnicity & Disease 2006 16:9-15
  17. Town T, Tan J, Flavell RA, Mullan M. T-cells in Alzheimer's disease.  Neuromolecular Med. 2005;7(3):255-64
  18. Ait-Ghezala G, Mathura VS, Laporte V, Quadros A, Paris D, Patel N, Volmar CH, Kolippakkam D, Crawford F, Mullan M. Genomic regulation after CD40 stimulation in microglia: relevance to Alzheimer's disease.  Brain Res Mol Brain Res. 2005 Oct 31;140(1-2):73-85.
  19. Patel NS, Paris D, Mathura V, Quadros AN, Crawford FC, Mullan MJ. Inflammatory cytokine levels correlate with ß-amyloid load in transgenic mouse models of Alzheimer's disease.  J Neuroinflammation. 2005 Mar 11;2(1):9.
  20. Paris D, Quadros A, Patel N, DelleDonne A, Humphrey J, Mullan M. Inhibition of angiogenesis and tumor growth by beta and gamma-secretase inhibitors.  Eur J Pharmacol. 2005 May 2;514(1):1-15.
  21. Paris D, Ait-Ghezala G, Mathura VS, Patel N, Quadros A, Laporte V, Mullan M. Anti-angiogenic activity of the mutant Dutch A(beta) peptide on human brain microvascular endothelial cells.  Brain Res Mol Brain Res. 2005 May 20;136(1-2):212-30
  22. Mathura VS, Paris D, Ait-Ghezala G, Quadros A, Patel NS, Kolippakkam D, Volmar CH, Mullan MJ. Model of Alzheimer's disease ß-amyloid peptide based on a RNA binding protein.  Biochem Biophys Res Commun. 2005 Jul 1;332(2):585-92
  23. Daniel Paris, Amita Quadros, James Humphrey, Nikunj Patel, Robert Crescentini, Fiona Crawford and Michael Mullan. Nilvadipine antagonizes both A beta vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice.  Brain Research 2004 Feb 27;999(1):53-61.
  24. Mott RT, Ait-Ghezala G, Town T, Mori T, Vendrame M, Zeng J, Ehrhart J, Mullan M, Tan J. Neuronal expression of CD22: novel mechanism for inhibiting microglial proinflammatory cytokine production.  Glia. 2004 May;46(4):369-79
  25. Sun J, Blaskovich MA, Jain RK, Delarue F, Paris D, Brem S, Wotoczek-Obadia M, Lin Q, Coppola D, Choi K, Mullan M, Hamilton AD, Sebti SM. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor  Cancer Res. 2004 May 15;64(10):3586-92
  26. Todd Roach J, Volmar CH, Dwivedi S, Town T, Crescentini R, Crawford F, Tan J, Mullan M. Behavioral effects of CD40-CD40L pathway disruption in aged PSAPP mice  Brain Res. 2004 Jul 23;1015(1-2):161-8
  27. Paris D, Patel N, DelleDonne A, Quadros A, Smeed R, Mullan M. Impaired angiogenesis in a transgenic mouse model of cerebral amyloidosis  Neurosci Lett. 2004 Aug 5;366(1):80-5
  28. Paris D, Townsend K, Quadros A, Humphrey J, Sun J, Brem S, Wotoczek-Obadia M, DelleDonne A, Patel N, Obregon DF, Crescentini R, Abdullah L, Coppola D, Rojiani AM, Crawford F, Sebti SM, Mullan M. Inhibition of angiogenesis by Abeta peptides  Angiogenesis. 2004;7(1):75-85
  29. Harwood DG, Barker WW, Ownby RL, Mullan M, Duara R. No association between subjective memory complaints and apolipoprotein E genotype in cognitively intact elderly  Int J Geriatr Psychiatry. 2004 Dec;19(12):1131-9
  30. Harwood DG, Barker WW, Ownby RL, St George-Hyslop P, Mullan M, Duara R. Apolipoprotein E polymorphism and age of onset for Alzheimer's disease in a bi-ethnic sample  Int Psychogeriatr. 2004 Sep;16(3):317-26
  31. Paris D, Humphrey J, Quadros A, Patel N, Crescentini R, Crawford F, Mullan M. Vasoactive effects of A beta in isolated human cerebrovessels and in a transgenic mouse model of Alzheimer's disease: role of inflammation. Neurol Res. 2003 Sep;25(6):642-51.
  32. Crawford FC, Ait-Ghezala G, Morris M, Sutcliffe MJ, Hauser RA, Silver AA, Mullan MJ. Translocation breakpoint in two unrelated Tourette syndrome cases, within a region previously linked to the disorder.  Hum Genet. 2003 Jul;113(2):154-61. Epub 2003 Apr 16.
  33. Quadros A, Patel N, Crescentini R, Crawford F, Paris D, Mullan M. Increased TNFalpha production and Cox-2 activity in organotypic brain slice cultures from APPsw transgenic mice.  Neurosci Lett. 2003 Dec 15;353(1):66-8.
  34. Townsend KP, Obregon D, Quadros A, Patel N, Volmar Ch, Paris D, Mullan M. Proinflammatory and vasoactive effects of Abeta in the cerebrovasculature.  Ann N Y Acad Sci. 2002 Nov;977:65-76
  35. Paris D, Townsend KP, Obregon DF, Humphrey J, Mullan M. Pro-inflammatory effect of freshly solubilized ß-amyloid peptides in the brain.  Prostaglandins Other Lipid Mediat. 2002 Sep;70(1-2):1-12.
  36. Tan J, Town T, Crawford F, Mori T, DelleDonne A, Crescentini R, Obregon D, Flavell RA, Mullan MJ. "ROLE OF CD40 LIGAND IN AMYLOIDOSIS IN TRANSGENIC ALZHEIMER'S MICE" Published in Nature Neuroscience on 10/28/02. Nat Neurosci. 5 Dec 2002;(12):1288-93.
  37. Yuspeh RL, Vanderploeg RD, Crowell TA, Mullan M. Differences in executive functioning between Alzheimer's disease and subcortical ischemic vascular dementia.  J Clin Exp Neuropsychol. 2002 Sep;24(6):745-54.
  38. Town T, Vendrame M, Patel A, Poetter D, DelleDonne A, Mori T, Smeed R, Crawford F, Klein T, Tan J, Mullan M. Reduced Th1 and enhanced Th2 immunity after immunization with Alzheimer's ß-amyloid(1-42).  J Neuroimmunol. 2002 Nov;132(1-2):49-59.
  39. Tan J, Town T, Abdullah L, Wu Y, Placzek A, Small B, Kroeger J, Crawford F, Richards D, Mullan M. CD45 isoform alteration in CD4+ T cells as a potential diagnostic marker of Alzheimer's disease.  J Neuroimmunol. 2002 Nov;132(1-2):164-72.
  40. Tan J, Town T, Mullan M. CD40-CD40L interaction in Alzheimer's disease.  Curr Opin Pharmacol. 2002 Aug;2(4):445-51.
  41. Town T, Zolton J, Shaffner R, Schnell B, Crescentini R, Wu Y, Zeng J, DelleDonne A, Obregon D, Tan J, Mullan M. p35/Cdk5 pathway mediates soluble ß-amyloid peptid e-induced tau phosphorylation in vitro.  J Neurosci Res. 2002 Aug 1;69(3):362-72
  42. Schinka JA, Town T, Abdullah L, Crawford FC, Ordorica PI, Francis E, Hughes P, Graves AB, Mortimer JA, Mullan M. A functional polymorphism within the mu-opioid receptor gene and risk for abuse of alcohol and other substances.  Mol Psychiatry. 2002;7(2):224-8.
  43. Ait-Ghezala G, Abdullah L, Crescentini R, Crawford F, Town T, Singh S, Richards D, Duara R, Mullan M. Confirmation of association between D10S583 and Alzheimer's disease in a case--control sample.  Neurosci Lett. 2002 Jun 7;325(2):87-90.
  44. Tan J, Town T, Mori T, Obregon D, Wu Y, DelleDonne A, Rojiani A, Crawford F, Flavell RA, Mullan M. CD40 is expressed and functional on neuronal cells.  EMBO J. 2002 Feb 15;21(4):643-652.
  45. Ait-Ghezala G, Abdullah L, Crescentini R, Crawford F, Town T, Singh S, Richards D, Duara R, Mullan M. Confirmation of association between D10S583 and Alzheimer's disease in a case-control sample. Neurosci Lett. 2002 Jun 7;325(2):87-90.
  46. Paris D, Townsend KP, Humphrey J, Obregon DF, Yokota K, Mullan M.Statins inhibit A beta-neurotoxicity in vitro and A beta-induced vasoconstriction and inflammation in rat aortae. Atherosclerosis. 2002 Apr;161(2):293-9
  47. Harwood DG, Barker WW, Ownby RL, Mullan M, Duara R. Apolipoprotein E polymorphism and cognitive impairment in a bi-ethnic community-dwelling elderly sample. Alzheimer Dis Assoc Disord. 2002 Jan-Mar;16(1):8-14
  48. Schinka JA, Town T, Abdullah L, Crawford FC, Ordorica PI, Francis E, Hughes P, Graves AB, Mortimer JA, Mullan M. A functional polymorphism within the mu-opioid receptor gene and risk for abuse of alcohol and other substances. Mol Psychiatry. 2002;7(2):224-8.
  49. Russ C, Powell JF, Zhao J, Baker M, Hutton M, Crawford F, Mullan M, Roks G, Cruts M, Lovestone S. The microtubule associated protein Tau gene and Alzheimer's disease--an association study and meta-analysis. Neurosci Lett. .2001 Nov 13;314(1-2):92-6
  50. Crawford FC, Vanderploeg RD, Freeman MJ, Singh S, Waisman M, Michaels L, Abdullah L, Warden D, Lipsky R, Salazar A, and Mullan MJ. APOE genotype influences acquisition and recall following traumatic brain injury. Neurology. 2002 58(7); 1115-1118
  51. Town T, Tan J, Mullan M. CD40 signaling and Alzheimer's disease pathogenesis. Neurochem Int. 2001 Nov-Dec;39(5-6):371-80. Review
  52. Town T, Tan J, Sansone N, Obregon D, Klein T, Mullan M. Characterization of murine immunoglobulin G antibodies against human amyloid-beta1-42. Neurosci Lett. 2001 Jul 13;307(2):101-4.
  53. Mori T, Paris D, Town T, Rojiani AM, Sparks DL, Delledonne A, Crawford F, Abdullah LI, Humphrey JA, Dickson DW, Mullan MJ. Cholesterol Accumulates in Senile Plaques of Alzheimers Disease Patients and in Transgenic APPsw Mice. Journal of Neuropathology and Experimental Neurology 2001 60(8): 778-85.
  54. Crawford FC, Freeman MJ, Schinka JA, Morris MD, Abdullah LI, Richards D, Sevush S, Duara R, Mullan MJ. Association between Alzheimer's disease and a functional polymorphism in the Myeloperoxidase gene. Experimental Neurology 2001 167(2):456-459.
  55. Town T, Schinka J, Tan J, Mullan M. The opioid receptor system and alcoholism: a genetic perspective. Eur J Pharmacol. 2000 Dec 27;410(2-3):243-248. Review.
  56. Crawford F, Abdullah L, Schinka J, Suo Z, Gold M, Duara R, Mullan M. Gender-specific association of the angiotensin converting enzyme gene with Alzheimer's disease. Neuroscience Letters 2000 280(3): 215-9.
  57. Suo Z, Su G, Placzek A, Kundtz A, Humphrey J, Crawford F, Mullan M. A beta vasoactivity in vivo. Ann N Y Acad Sci. 2000 Apr;903:156-63.
  58. Crawford F, Freeman M, Abdullah L, Schinka J, Gold M, Duara R, Mullan M. No association between the NOS3 codon 298 polymorphism and Alzheimer's disease in a sample from the United States. Ann Neurol. 2000 May;47(5):687. 
  59. Kuo YM, Crawford F, Mullan M, Kokjohn TA, Emmerling MR, Weller RO, Roher AE. Elevated A beta and apolipoprotein E in A betaPP transgenic mice and its relationship to amyloid accumulation in Alzheimer's disease. Mol Med. 2000 May;6(5):430-9.
  60. Small BJ, Graves AB, McEvoy CL, Crawford FC, Mullan M, Mortimer JA. Is APOE--epsilon4 a risk factor for cognitive impairment in normal aging? Neurology. 2000 Jun 13;54(11):2082-8
  61. Sevush S, Peruyera G, Crawford F, Mullan M. Apolipoprotein-E epsilon 4 allele frequency and conferred risk for Cuban Americans with Alzheimer's disease. Am J Geriatr Psychiatry. 2000 Summer;8(3):254-6.
  62. Crawford FC, Freeman MJ, Schinka JA, Abdullah LI, Gold M, Hartman R, Krivian K, Morris MD, Richards D, Duara R, Anand R, Mullan MJ. A polymorphism in the cystatin C gene is a novel risk factor for late-onset Alzheimer's disease. Neurology. 2000 Sep 26;55(6):763-8.
  63. Tan J, Town T, Mullan M. CD45 inhibits CD40L-induced microglial activation via negative regulation of the Src/p44/42 MAPK pathway. J Biol Chem. 2000 Nov 24;275(47):37224-31.
  64. Tan J, Town T, Mori T, Wu Y, Saxe M, Crawford F, Mullan M. CD45 opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activated protein kinase. J Neurosci. 2000 Oct 15;20(20):7587-94.
  65. Tandon A, Rogaeva E, Mullan M, St George-Hyslop PH. Molecular genetics of Alzheimer's disease: the role of beta-amyloid and the presenilins. Curr Opin Neurol. 2000 Aug;13(4):377-84. Review.
  66. Paris D, Town T, Mori T, Parker TA, Humphrey J, Mullan M. Soluble beta-amyloid peptides mediate vasoactivity via activation of a pro-inflammatory pathway. Neurobiol Aging. 2000 Mar-Apr;21(2):183-97.
  67. Paris D, Town T, Humphrey J, Yokota K, Mullan M. Cholesterol modulates vascular reactivity to endothelin-1 by stimulating a pro-inflammatory pathway. Biochem Biophys Res Commun. 2000 Aug 2;274(2):553-8.
  68. Crawford FC, Freeman MJ, Schinka J, Abdullah LI, Richards D, Sevush S, Duara R, Mullan MJ. The genetic association between Cathepsin D and Alzheimer's disease. Neurosci Lett. 2000 Jul 28;289(1):61-5.
  69. Paris D, Town T, Parker T, Humphrey J, Mullan M. beta-Amyloid vasoactivity and proinflammation in microglia can be blocked by cGMP-elevating agents. Ann N Y Acad Sci. 2000 Apr;903:446-50.
  70. Paris D, Town T, Parker T, Humphrey J, Mullan M. A beta vasoactivity: an inflammatory reaction. Ann N Y Acad Sci. 2000 Apr;903:97-109.
  71. Paris D, Town T, Mullan M. Novel strategies for opposing murine microglial activation. Neurosci Lett. 2000 Jan 7;278(1-2):5-8.
  72. Tan J, Town T, Paris D, Mori T, Suo Z, Crawford F, Mattson MP, Flavell RA, Mullan M. Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science. 1999 Dec 17;286(5448):2352-5.
  73. Tan J, Town T, Saxe M, Paris D, Wu Y, Mullan M. Ligation of microglial CD40 results in p44/42 mitogen-activated protein kinase-dependent TNF-alpha production that is opposed by TGF-beta 1 and IL-10. J Immunol. 1999 Dec 15;163(12):6614-21
  74. Tan J, Town T, Suo Z, Wu Y, Song S, Kundtz A, Kroeger J, Humphrey J, Crawford F, Mullan M. Induction of CD40 on human endothelial cells by Alzheimer's beta-amyloid peptides. Brain Res Bull. 1999 Sep 15;50(2):143-8.
  75. King DL, Arendash GW, Crawford F, Sterk T, Menendez J, Mullan MJ. Progressive and gender-dependent cognitive impairment in the APP(SW) transgenic mouse model for Alzheimer's disease. Behav Brain Res. 1999 Sep;103(2):145-62.
  76. Tan J, Town T, Placzek A, Kundtz A, Yu H, Mullan M. Bcl-X(L) inhibits apoptosis and necrosis produced by Alzheimer's beta-amyloid1-40 peptide in PC12 cells. Neurosci Lett. 1999 Sep 3;272(1):5-8.
  77. Town T, Paris D, Parker TA, Kundtz A, Tan J, Duara R, Gold M, Crawford F, Mullan M. Alzheimers disease is not associated with the hypertension genetic risk factors PLA(2) or G protein beta3, either independently or interactively with apolipoprotein E. Am J Med Genet. 1999 Oct 15;88(5):465-8.
  78. Town T, Abdullah L, Crawford F, Schinka J, Ordorica PI, Francis E, Hughes P, Duara R, Mullan M. Association of a functional mu-opioid receptor allele (+118A) with alcohol dependency. Am J Med Genet. 1999 Oct 15;88(5):458-61.
  79. Crawford F, Freeman M, Town T, Fallin D, Gold M, Duara R, Mullan M. No genetic association between polymorphisms in the Tau gene and Alzheimer's disease in clinic or population based samples. Neurosci Lett. 1999 May 14;266(3):193-6.
  80. Crawford F, Town T, Freeman M, Schinka J, Gold M, Duara R, Mullan M. The alpha-2 macroglobulin gene is not associated with Alzheimer's disease in a case-control sample. Neurosci Lett. 1999 Aug 6;270(3):133-6.
  81. Tan, J, Town T, Paris D, Placzek A, Parker T, Crawford F, Yu H, Humphrey J, Mullan M. Activation of microglial cells by the CD40 pathway: relevance to multiple sclerosis. Journal of Neuroimmunology. 1999 Jun 1;97(1-2):77-85.
  82. Arendash GW, Su GC, Crawford FC, Bjugstad KB, Mullan M. Intravascular beta-amyloid infusion increases blood pressure: implications for a vasoactive role of beta-amyloid in the pathogenesis of Alzheimer's disease. Neurosci Lett. 1999 Jun 11;268(1):17-20.
  83. Paris D, Town T, Parker T, Tan J, Humphrey J, Crawford F, & Mullan M. Inhibition of Alzheimers ß-amyloid induced vasoactivity and proinflammatory response in Microglia by cGMP-dependent Mechanism Experimental Neurology, 1999 157 (1):221-221
  84. Pompl PN, Mullan MJ, Bjugstad K, Arendash GW. Adaptation of the circular platform spatial memory task for mice: use in detecting cognitive impairment in the APP(SW) transgenic mouse model for Alzheimer's disease. J Neurosci Methods. 1999 Feb 1;87(1):87-95.
  85. Harwood DG, Barker WW, Loewenstein DA, Ownby RL, St George-Hyslop P, Mullan M, Duara R. A cross-ethnic analysis of risk factors for AD in white Hispanics and white non-Hispanics. Neurology. 1999 Feb;52(3):551-6.
  86. Su GC, Arendash GW, Kalaria RN, Bjugstad KB, Mullan M. Intravascular infusions of soluble beta-amyloid compromise the blood-brain barrier, activate CNS glial cells and induce peripheral hemorrhage. Brain Res. 1999 Feb 6;818(1):105-17.
  87. Town T, Paris D, Parker T, Kundtz A, Fallin D, Tan J, Crawford F, Mullan M.  Lack of association between the Hypertension risk factors pancreatic PLA2 or G protein b3 either independently or interactively with apolipoprotein E on Alzheimer's disease. American Journal of Medical Genetics (Neuropsychiatric Genetics)
  88. Pompl PN, Mullan M, Bjugstad K, Arendash G. Adaptation of the circular platform spatial memory task for mice: use in detecting cognitive impairment in the APP(SW) transgenic mouse model for AD. Journal or Neuroscience Methods 1999 Feb 1;87(1): 87-95.
  89. Su GC, Arendash GW, Kalaria RN, Bjugstad KB, Mullan M. Intravascular infusions of soluble A?compromise the blood-brain barrier, activate CNS glial cells and induce peripheral hemorrhage. Brain Res 1999 818 (1): 105-17.
  90. Paris D, Town T, Parker T, Tan J, Humphrey J, Crawford F, Mullan M. Inhibition of Alzheimer's A?induced Vasoactivity and Proinflammatory response in Microglia by cGMP-Dependent Mechanism. Exp. Neurol. 1999 May;157(1): 211-221.
  91. Paris D, Suo Z, Parker T, Town T, Fang C, Humphrey J, Crawford F, Mullan M. Role of Peroxynitrite in the vasoactive and cytotoxic effects of Alzheimer's ß-amyloid1-40 peptide. Experimental Neurology 1998 Jul;152(1):116-22.
  92. Suo Z, Humphrey J, Kundtz A, Sethi F, Placzek A, Crawford F, Mullan M. Soluble Alzheimer's ß-amyloid constricts the cerebral vasculature in vivo. Neuroscience Letters 1998 257(2): 77-80.
  93. Paris D, Town T, Parker TA, Humphrey J, Mullan M. Isoform-specific vasoconstriction induced by apolipoprotein E and modulation of this effect by Alzheimer's beta-amyloid peptide. Neuroscience Letters 1998 256(2): 73-76.
  94. Town T, Paris D, Fallin D, Duara R, Barker W, Crawford F, Mullan M. The -491A/T assocation with Alzheimer's disease: independent risk and linkage disequilibrium with the epsilon alleles. Neuroscience Letters 1998 252(2): 95-8.
  95. Crawford F, Fallin D, Suo Z, Abdullah L, Gold M, Gauntlett A, Duara R, Mullan M. The Butyrylcholinesterase gene is neither independently nor synergistically associated with late-onset AD in clinic and community-based populations. Neuroscience Letters 1998 249(2-3), 115-118.
  96. Crawford F, Soto C, Suo Z, Fang C, Parker T, Sawar A, Frangione B, Mullan M. Vasoactivity of Amyloid- Conformational Intermediates: Implications for the Vascular Pathology in Alzheimer's Disease FEBS Letters 1998 436(3): 445-8.
  97. Suo Z, Tan J, Placzek A, Crawford F, Fang C, Mullan M. Alzheimer's -Amyloid Peptides Induce Inflammatory Cascades in Human Vascular Cells: the roles of cytokines and CD40. Brain Research 1998 807 (1-2): 110-117.
  98. Crawford F, Suo ZM, Fang CH, Mullan M Characteristics of the in vitro vasoactivity of beta-amyloid peptides Exp Neurol. 1998 Mar;150(1):159-68
  99. Suo Z, Crawford F, Placzek A, Paris D, Fang C, Mullan M. Phenyl-N-Tert-Butyl Nitrone neutralizes the activities of ß-amyloid peptide on both cultured cells and isolated vessels via multiple pathways. Alzheimer's Reports 1998 Vol.1(6).

Top | Home